A Cornell University-led collaboration has uncovered the equipment that enables bacteria to survive exposure to antibiotics: ...

AbbVie has claimed FDA approval for Emblaveo, a new antibiotic product to treat complicated intra-abdominal infections (cIAI) ...

Research into developing new antimicrobial resistance treatments in Nigeria and other low/middle-income countries has secured ...

A study reveals alarming rates of antibiotic resistance in Gram-negative bacteria, highlighting the urgent need for ...

GR was a paid consultant to Cubist Pharmaceuticals on a previous project on "Clinical and economic consequences of hospital-acquired resistant and multidrug-resistant pseudomonas aeruginosa ...

AbbVie has announced that the US Food and Drug Administration (FDA) has approved its Pfizer-partnered Emblaveo ...

Ten months after Pfizer scored approval in Europe for Emblaveo (aztreonam and avibactam) to treat complicated intra-abdominal infections (cIAIs), AbbVie has done the same in the U.S., ...

CAMBRIDGE, MA AND PITTSBURGH, PA / ACCESSWIRE / 10, 2025 / Next Gen Diagnostics (NGD), a pioneer in the development of machine learning models for whol ...

It's the first and only such therapy approved to fight antimicrobial resistance, or AMR, in bacterial infections.

The intravenous antibiotic Emblaveo, a combination of aztreonam and avibactam approved in Europe last year, was developed in ...

Emblaveo (aztreonam-avibactam) was approved for treating complicated intra-abdominal infections with limited or no treatment ...

Emblaveo will be available in the third quarter of 2025 to treat patients with intra-abdominal infections, a common cause of sepsis in the intensive care unit.